Zacks Research Has Positive View of Cencora FY2025 Earnings

Key Points

• Zacks Research has updated its FY2025 earnings estimate for Cencora, predicting earnings per share will rise to $15.94, an increase from a previous forecast of $15.70.
• Cencora reported a quarterly EPS of $4.00, beating estimates by $0.21, along with a revenue increase of 8.7% year-over-year.
• The company will distribute a quarterly dividend of $0.55 per share on September 3rd, reflecting an annualized yield of 0.8%.

Cencora, Inc. (NYSE:COR - Free Report) - Investment analysts at Zacks Research upped their FY2025 earnings estimates for Cencora in a research report issued on Wednesday, August 27th. Zacks Research analyst Team now expects that the company will post earnings per share of $15.94 for the year, up from their previous forecast of $15.70. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora's Q4 2025 earnings at $3.79 EPS, Q1 2026 earnings at $4.10 EPS, Q2 2026 earnings at $4.80 EPS, Q3 2026 earnings at $4.35 EPS, Q4 2026 earnings at $3.99 EPS, FY2026 earnings at $17.24 EPS, Q1 2027 earnings at $4.29 EPS, Q2 2027 earnings at $5.30 EPS, Q3 2027 earnings at $4.85 EPS and FY2027 earnings at $19.18 EPS.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating analysts' consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same period last year, the company posted $3.34 EPS. Cencora's quarterly revenue was up 8.7% compared to the same quarter last year.

A number of other brokerages have also issued reports on COR. Citigroup lifted their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Jefferies Financial Group raised their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday, June 30th. Wells Fargo & Company upped their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Finally, Robert W. Baird increased their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and an average price target of $311.25.

Cencora Price Performance

Shares of Cencora stock opened at $291.51 on Monday. The stock has a market capitalization of $56.52 billion, a P/E ratio of 29.99, a PEG ratio of 1.38 and a beta of 0.62. The business has a 50 day simple moving average of $293.02 and a two-hundred day simple moving average of $282.41. Cencora has a 12 month low of $218.65 and a 12 month high of $309.35. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Institutional Investors Weigh In On Cencora

A number of institutional investors and hedge funds have recently made changes to their positions in COR. Atlantic Edge Private Wealth Management LLC raised its position in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company's stock valued at $25,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC boosted its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after purchasing an additional 48 shares during the period. Hoey Investments Inc. acquired a new position in shares of Cencora in the first quarter worth $28,000. Costello Asset Management INC purchased a new stake in Cencora during the 1st quarter worth about $28,000. Finally, Banque Transatlantique SA purchased a new stake in shares of Cencora during the fourth quarter worth approximately $29,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at $12,455,852.61. The trade was a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the transaction, the chairman directly owned 309,913 shares in the company, valued at approximately $90,702,237.71. This trade represents a 4.49% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,125 shares of company stock valued at $9,993,789. 10.80% of the stock is owned by insiders.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, August 15th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Cencora's dividend payout ratio is presently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.